How ingredient suppliers manage multi-market SDS at scale.

Most ingredient suppliers start with a folder per product, a sub-folder per market and a Word template the regulatory team copies and edits. It works for fifty SKUs in three regions. It fails at three hundred SKUs in twenty regions, and it fails spectacularly the first time CLP, GHS or a national variant moves and the team has to re-author the entire library.

The failure modes are predictable. SDSs drift between markets because the local regulatory affairs lead edited a section without telling head office. Translations fall behind because the in-country agent is on holiday. Customers receive different SDSs for the same lot because two versions are live at once. None of this is negligence. It is the inevitable consequence of treating the SDS as the source of truth instead of as an output.

The architecture that scales is substance-first. Each substance has one record. That record holds CAS number, EC number, INCI where applicable, every classification under GHS and its national variants (CLP, OSHA HazCom, K-REACH, J-GHS, China GHS, Australia GHS), every hazard statement and precautionary statement, every exposure limit, every transport classification (UN, ADR, IMDG, IATA), and every regulatory flag (SVHC, Annex XVII, Prop 65, TSCA inventory).

An SDS for a given product in a given market is not authored. It is generated. The 16-section structure pulls the right fields from the substance master, the mixture calculator applies the relevant mixture rules, and the translation layer renders the hazard and precautionary phrases from a controlled library. Authoring time per new market drops from days to minutes.

The expensive mistake is to treat SDS translation as free-text translation. It is not. The hazard statements, precautionary statements and headings are controlled vocabularies, with official translations published by the regulator. A scaled SDS system pins those phrases to a translation memory keyed off the official phrase ID (H315, P302+P352 and so on), so the translation work is one-time and reused.

The free-text fields, supplier identification, emergency contact, specific use instructions, are a small fraction of the document. They are the only fields a human translator needs to touch. A team of three can keep an entire portfolio translated into twenty languages with this approach. Without it, you need thirty.

An SDS is a regulated document with a customer obligation. When you issue a new version, you have a duty to push it to customers who received the previous one within the lookback window (twelve months in most regimes, longer in some). Email attachments break this: there is no record of who received what, and no record of when.

The right architecture: every customer has a portal account. Every SDS issued to them is logged with version, lot and date. When a new version is issued, the portal serves the new one, the old one is archived with provenance, and the customer is notified. Read receipts close the loop. The regulator audit becomes a query, not a panic.

CLP changes. GHS moves through the Globally Harmonised System revisions. K-REACH tightens. Prop 65 adds substances. The SDS library has to keep up, and the team that catches the change first wins the next two weeks back.

The scaled approach: regulator feeds (ECHA, EPA, MHRA, METI, NMPA, Australian Department of Health) are ingested into the substance master automatically. When a classification changes, the affected substances surface, the affected SDSs are flagged, drafts are generated for review and customer distribution is queued. The regulatory team makes decisions, not transcripts.

With substance-first authoring, controlled translation memory and portal distribution, a portfolio of five hundred substances across twenty markets and twenty languages can be run by a regulatory affairs team of five to seven. With the folder-of-PDFs model, the same portfolio routinely needs twenty-five to forty, and the documents are still out of date.